Jul 5, 2024, 02:47
A new standard for treating limited-stage small cell lung cancer – Sarah Cannon Research Institute
“Dr. David R. Spigel recently shared research on durvalumab and how it has set a new standard for treating limited-stage small cell lung cancer, offering improved survival rates for patients. Explore the impactful findings from the ADRIATIC trial here: [ADRIATIC Trial: A New Beginning For The Treatment of LS-SCLC].”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 17, 2024, 10:15
Sep 17, 2024, 10:01
Sep 17, 2024, 09:55
Sep 17, 2024, 09:42
Sep 17, 2024, 09:24
Sep 17, 2024, 09:15